Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke.

Elena A Tukhovskaya,Alina M Ismailova,Vadim T Ivanov,Oksana N Khokhlova,Gulsara A Slashcheva,Arkady N Murashev,Igor A Prudchenko,Inessa I Mikhaleva,Elvira R Shaykhutdinova

doi:10.3390/molecules26175173

Elena A Tukhovskaya, Alina M Ismailova + Show 7 more

Open Access

https://doi.org/10.3390/molecules26175173

Copy DOI

Abstract

Background and Objectives: Mutual effect of the preliminary and therapeutic intranasal treatment of SD rats with DSIP (8 days) on the outcome of focal stroke, induced with intraluminal middle cerebral occlusion (MCAO), was investigated. Materials and Methods: The groups were the following: MCAO + vehicle, MCAO + DSIP, and SHAM-operated. DSIP or vehicle was applied nasally 60 (±15) minutes prior to the occlusion and for 7 days after reperfusion at dose 120 µg/kg. The battery of behavioral tests was performed on 1, 3, 7, 14, and 21 days after MCAO. Motor coordination and balance and bilateral asymmetry were tested. At the end of the study, animals were euthanized, and their brains were perfused, serial cryoslices were made, and infarction volume in them was calculated. Results: Although brain infarction in DSIP-treated animals was smaller than in vehicle-treated animals, the difference was not significant. However, motor performance in the rotarod test significantly recovered in DSIP-treated animals. Conclusions: Intranasal administration of DSIP in the course of 8 days leads to accelerated recovery of motor functions.

Highlights

Delta sleep-inducing peptide (DSIP) is a multifunctional regulatory peptide
DSIP acts as an adaptogen at amphetamine-induced stereotypy, which is a model of schizophrenia-like condition in humans
Konorova et al elucidated the ability of DSIP to reduce the lethality of stress in low-resistant rats [22]

Summary

Introduction

Delta sleep-inducing peptide (DSIP) is a multifunctional regulatory peptide. It was first isolated from cerebral venous blood of rabbits after low-frequency (‘hypnogenic’) electrical stimulation of the intralaminar thalamic nuclei by the Schoenenberger–Monnier group from Basel in 1977 [1]. DSIP acts as an adaptogen at amphetamine-induced stereotypy, which is a model of schizophrenia-like condition in humans It normalizes brain metabolism injured with long-term amphetamine treatment. The treatment of Wistar rats with DSIP several hours prior to global brain ischemia improved locomotor functions and reduced lethality [23]. DSIP reduced neuronal activity and improved blood supply of the brain of stressed animals subjected to brain ischemia [24]. Investigation of DSIP at a model of carotid arteries occlusion in different age groups of male rats revealed DSIP’s ability to correct the impaired balance of brain neuromediators hypoxia [25]. Mutual effect of the preliminary and therapeutic intranasal treatment of SD rats with DSIP (8 days) on the outcome of focal stroke, induced with intraluminal middle cerebral occlusion (MCAO), was investigated. Conclusions: Intranasal administration of DSIP in the course of 8 days leads to accelerated recovery of motor functions

Objectives

Methods

Results